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Chapter 4

Pharmacokinetics of Anticoagulant
Rodenticides in Target and Non-target
Organisms
Katherine E. Horak, Penny M. Fisher, and Brian Hopkins

1

Introduction

The concentration of a compound at the site of action is a determinant of its toxicity.
This principle is affected by a variety of factors including the chemical properties of
the compound (pKa, lipophilicity, molecular size), receptor binding affinity, route
of exposure, and physiological properties of the organism. Many compounds have
to undergo chemical changes, biotransformation, into more toxic or less toxic forms.
Because of all of these variables, predicting toxic effects and performing risk assessments of compounds based solely on dose are less accurate than those that include
data on absorption, distribution, metabolism (biotransformation), and excretion of
the compound. These factors are commonly referred to as ADME. The quantitative
study of these properties is called pharmacokinetics and often encompasses the
determination of compound concentrations in tissues of interest including blood and
the time course of absorption, metabolism, and excretion. A goal of pharmacokinetics is an understanding of the relationship between dose and the concentration of the
active compound at the target site. Toxicokinetics is a “unique expansion of pharmacokinetics”, with doses being much greater than those in pharmacokinetic studies (Welling 1995). This is a complicated task, especially for anticoagulant
rodenticides (ARs), as exposure (dose) frequently occurs over multiple days and
can result from consumption of poisoned animals containing varying concentration
of ARs and their metabolites, not simply a toxic bait.
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Although ARs have been in use for decades, there are limited data on the ADME
of these compounds for non-target animals. Most of the data have been derived from
laboratory strains of rodents as a traditional model system. Current understanding
of the pharmacokinetics (how the exposed animal affects the compound?) and pharmacodynamics (how the compound affects the exposed animal?) of ARs tend to
focus on how their toxic effects are mediated in a particular species (e.g., Littin et al.
2002). Such information is essential to predicting the efficacy of ARs in rodent
management and adverse effects of their use on non-target species, and allows for a
more accurate comparison of various classes of ARs (first-, intermediate- and
second-generation). When information about the ADME properties of an AR are
combined with data such as binding affinities and physiological/ecological characteristics of an organism, more accurate risk assessments can be made. These hazard
and risk assessments are important as the US EPA and other regulatory agencies
include pharmacokinetic data and models in their work plans and formal ecological
risk assessments.

2

Formulations

All ARs currently on the market are formulated into palatable baits for oral delivery
to targeted rodent pests. Typically, bait formulations are based on cereal grain made
into compressed blocks or pellets along with smaller portions of binding, flavoring,
non-target deterrents and coloring (blue or green) agents. A wax or water proofing
ingredient is included in some formulations. Such bait formulations impart low
production costs plus relative safety and ease of application, usually in a bait station.
Other types of specialized formulations do exist but have more limited applications
in particular environmental conditions, for example liquid concentrates that can be
diluted for use in areas where an abundant food source is present, or in areas where
there is little or no water supply. Similarly, concentrated anticoagulant tracking
powders are available for use when conventional baits may not be appropriate or
accepted (e.g., dusting into rat burrows that are likely to lead into buildings and into
wall voids which are not accessible for normal bait placement).

3

Routes of Exposure

While current bait formulations rely on voluntary ingestion of sufficient quantities
for efficacy against target animals, they also present the potential for unwanted
primary exposure of other animals that access and eat bait. Secondary oral exposure
to ARs can also occur via ingestion of animal tissues that contain AR residues; this
exposure pathway has emerged as a particular concern for wildlife species that prey
on rodents or scavenge the carcasses of poisoned animals.
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Besides their use as rodenticides some anticoagulant compounds, particularly
warfarin (2001) and historically diphacinone (e.g. Field et al. (1952)), have wide
application in human anticoagulation therapy. Human exposure to anticoagulants
through rodenticide bait can occur (Tran and King 2015; Watt et al. 2005) and is
most typically oral, whether accidental (e.g., exploratory ingestion by very young
children) or deliberate (e.g., attempts at self-harm) (e.g. Bruno et al. 2000). Less
commonly dermal (Spiller et al. 2003) or inhalation (Lee et al. 2014) exposure of
humans has been documented in the context of occupational exposure during manufacture or inappropriate application of bait for rodent control. Development and
refinement of human therapies and treatments for anticoagulant poisoning have substantially driven research and clinical evaluations of pharmacokinetics and responses
of blood coagulation indices (e.g., prothrombin time following treatment regimens
with Vitamin K1) (Hanslik and Prinseau 2004).

4

Absorption, Distribution, Metabolism and Excretion

A study by Subota et al. (2016) examined the absorption and physiological effects
of a dermally applied solution of sodium warfarin in laboratory rats (Rattus norvegicus). They found that dermal applications of 10 μg and 100 μg of warfarin significantly increased prothrombin time (PT) when compared to controls indicating that
the compound is absorbed through the skin in quantities sufficient to exert its pharmacological effect. The dermal absorption of the coumarin backbone of the class of
anticoagulants has also been studied. The absorption of coumarin in both ethanol
and oil:water emulsion was tested using both human and rat skin (Yourick and
Bronaugh 1997). In both human abdominal and rat dorsal skin, absorption was
greater in the emulsion vehicle and the majority of the absorption occurred within
six hours of application. No coumarin metabolism was found in these experiments,
suggesting that transdermal exposure to coumarins will result in a higher systemic
exposure to the active parent compound than oral exposure prior to first pass metabolism. Additional studies of skin absorption of coumarin also found that it was
extensively absorbed through human, rat, and mouse skin which was attributed to
the compound’s lipophilicity (Beckley-Kartey et al. 1997).
Active concentrations in bait are typically 0.02–0.05 g/kg for second-generation
ARs (SGARs) and 0.25–0.5 for the less potent first-generation ARs (FGARs). Here
we focus on oral exposure resulting from ingestion of bait containing an AR and
also ingestion of animal tissue that contains residual anticoagulant concentrations.
Anticoagulants are generally considered to be well-absorbed through the gastrointestinal tract (Watt et al. 2005), presumably within a few hours. Wright and Hayden
(1955) suggested that the efficacy of absorption of a coumarin derivative in rats
could be reduced by the presence of high fat levels in gut contents. Berny et al.
(2006) indicated that anticoagulants (warfarin, chlorophacinone and bromadiolone)
underwent very little, if any, degradation by microflora in sheep rumen.
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After absorption across the intestinal epithelium, anticoagulant compounds enter
the hepatic circulation prior to being distributed throughout the whole body of
mammals. In birds, a fraction of the blood from the gastrointestinal tract is directed
to the kidneys through the coccygeomesenteric vein. This can dramatically decrease
the anticoagulant concentration in the systemic circulation as the compounds are
metabolized by the liver largely through the action of cytochrome P450 isozymes
(CYPs). Ring hydroxylation is thought to be an important biotransformation step
for the coumarin-based anticoagulant compounds, although this is less well
described for the indandione compounds. Hydroxylated metabolites can further
undergo conjugation with glucuronic acid prior to entering the systemic circulation,
and potentially undergoing enterohepatic recirculation. This can affect the amount
of compound that reaches target locations. Enterohepatic recirculation of unmetabolized parent compound, may partly explain the higher toxicity of some of the
second-generation anticoagulants (Bachmann and Sullivan 1983).
Metabolism, distribution, and excretion of ARs are affected by numerous factors.
Hepatic metabolism of ARs exhibits a biphasic profile. Initial metabolism is rapid,
often clearing a large percentage of the compound within the first days following
exposure. In the terminal phase of hepatic metabolism, clearance of anticoagulant
compound occurs more slowly leading to the low residual levels of SGARs often
found for long periods of time post-exposure. Anticoagulant rodenticides, particularly warfarin, are highly protein-bound to serum albumin (Watt et al. 2005). This
affects their distribution to active sites and therefore necessitates higher bait concentrations to ensure adequate unbound compound is available to interact with target
proteins. Some second-generation ARs, such as brodifacoum and flocoumafen,
appear to undergo relatively little biotransformation being excreted largely as
unchanged parent compound in feces. This is in contrast to first-generation compounds that appear to undergo more extensive metabolism, with a range of metabolite compounds excreted in urine.
In addition to providing information about effects to the primary target animal, a
firm understanding of the ADME characteristics of ARs will help in assessing the
potential risks they pose to non-target species. The information provided below
serves as a summary of studies of the pharmacokinetics of AR in non-target species.
When examined together, these studies give a general understand of the ADME
characteristics of ARs in non-target species. However, the paucity of data on some
compounds and species indicate that additional studies should be undertaken to
improve our understanding of the potential effects across species.

4.1

Warfarin

Warfarin is a racemic mixture of the R and S stereoisomers with the (S)-isomer
having approximately seven-fold greater activity than the (R)-isomer (Breckenridge
and L’E Orme 1972). Cytochrome P450 mediated warfarin metabolism is well
established in mammalian species and has been employed as a determinant of

4

Pharmacokinetics of Anticoagulant Rodenticides in Target and Non-target Organisms

91

Table 4.1 Mean metabolic activities (pmol/min/nmol P450) of each of the hydroxylated forms of
warfarin in rat, chicken, ostrich and mallard (Anas platyrhynchos) owl includes snowy owl and
great horned owl
Species
Rat
Chicken
Ostrich
Mallard
Owl

4′-OH
92.8
1204.0
523.4
96.8
25.9

6′-OH
48.5
294.5
68.0
18.2
2.6

7′-OH
14.9
113.7
17.2
10.5
ND

8′-OH
2.3
43.4
30.4
ND
1.5

10′-OH
37.4
4.5
ND
9.1
ND

Total
196.0
1660.2
638.0
134.6
32.0

Adapted from Watanabe et al. (2010)

warfarin sensitivity. The stereoisomers are metabolized by different phase 1
enzymes; the predominant metabolism of the S isomer in humans is via CYP2C9
whereas metabolism of R-warfarin is mainly via CYP3A4 with involvement of
CYP1A1, CYP1A2, CYP2C8, CYP2C9, CYP2C18 and CYP2C19 (Rettie et al.
1992; Ngui et al. 2001; Zhang et al. 1995; Wienkers et al. 1996). In rats, CYP1A,
CYP2B, CYP2C, and CYP3A isoforms are known to metabolize warfarin
(Guengerich et al. 1982). This phase 1 metabolism is achieved through the production of relatively inactive hydroxywarfarins – 6-, 7-, 8-, 10-, and 4′-hydroxywarfarin
(Kaminsky and Zhang 1997; Jones and Miller 2011). It has been reported that one
of the mechanisms that induces warfarin-resistance in rats (Rattus rattus) is elevated
CYP-mediated warfarin metabolism (Ishizuka et al. 2007). Phase II metabolism of
warfarin has not been well studied, although it is known that sulfated and glucuronyl
conjugates (Sutcliffe et al. 1987) can be formed and that the primary metabolites are
made more water-soluble by phase II enzymes (Jansing et al. 1992). It has been suggested that the glucuronide metabolites are principally formed in the kidney in man
(Kaminsky and Zhang 1997). Elimination of warfarin is predominantly renal; however, salivary excretion has also been described in rabbits (Sakai et al. 1983).
In contrast to rats, it appears that the major CYP isoforms of bird species are different to the predominant isoforms in mammals. The dominant CYP isoforms of
bird species are thought to be CYP2H1/2 (resembles rat CYP2B1/2), CYP1A4/5
(resembles rat CYP1A1/2) or an inducible form that resembles rat CYP2E (Louis
et al. 1993). Some bird species demonstrate a warfarin metabolic activity that is
significantly greater than in rats (e.g., in chickens, Gallus domesticus, warfarin metabolic activity to hydroxylated forms of warfarin was observed to be >5-fold greater
than rats). However, such activity is quite variable among avian species (Table 4.1).
This difference in activity between mammals and birds and among avian species
corresponds directly to the rank order of warfarin susceptibility, as demonstrated in
owls (snowy owl, Bubo scandiacus and great horned owl, Bubo virginianus) which
show very little warfarin metabolism compared with rodents and other bird species.
This low metabolism may also slow the elimination rate of warfarin which suggests that owls possess a low ability to detoxify anticoagulant rodenticides in general, a contributing factor perhaps to the high frequency of reported poisoning
accidents in these species. In addition to the usual five major hydroxylated metabolites identified in mammals, birds also appear to produce a unique warfarin alcohol

92

K.E. Horak et al.

metabolite (Table 4.1) (Watanabe et al. 2010). This suggests that birds have an ability to uniquely metabolize warfarin, which differs from that of rats and human
(Rettie et al. 1992; Ngui et al. 2001). Saengtienchai et al. (2011) propose that in
chickens, this is through activity of aldehyde oxidase in cytosol rather than being a
CYP-mediated pathway.
Interestingly, another study by the same group (Watanabe et al. 2015) found that
the half-life of warfarin in chicken was longer than in most mammalian species that
possess greater warfarin metabolic ability. This suggests that protein binding of
warfarin in the chicken (primarily to albumin in the plasma) may be greater in birds
which results in the longer half-life and less toxicity despite the high metabolic ability. Watanabe and coworkers postulated that since the albumin content in birds is
less than in mammals, it might have greater warfarin-binding capacity. In regards to
other bird species, Watanabe et al. (2015) also characterized warfarin metabolism in
liver microsomes of the crow (Corvus macrorhynchos), mallard and ostrich (Struthio
camelus). Microsomes from chickens and crows had higher activity than those from
mallard or ostrich, further suggesting that the half-life of warfarin may be variable
among avian species.
Warfarin has been shown to interact with the ABCB1 transporter in human liver
(Wadelius et al. 2004). In modelling human pharmacodynamics, Holford (1986)
determined that warfarin is essentially completely absorbed, reaching a maximum
plasma concentration between 2 and 6 h. It distributes into a small volume of distribution (10 L/70 kg) and is eliminated with a very low clearance (0.2 L/h/70 kg) and
elimination half-life is about 35 h (Holford 1986). Warfarin also undergoes extensive biliary (enterohepatic) recycling with approximately 10% of administered dose
of 14C–warfarin excreted by rats within 5 h after intraperitoneal injection (Powell
et al. 1977). This latter study found relatively little radioactivity in the feces, indicating that considerable enterohepatic recycling takes place with extensive gut floramediated hydrolysis of warfarin conjugates occurring. This was confirmed by
Remmel and coworkers (1981) who identified that there was a significant decrease
in the volume of distribution of warfarin in antibiotic-treated rats.
The time course of warfarin concentrations in the serum, liver, kidneys, muscle,
and abdominal fat of male Sprague-Dawley rats after intravenous injection of a
0.25 mg/kg or 1.0 mg/kg body weight has been determined (Levy et al. 2003).
Warfarin concentrations in serum declined exponentially by over one order of magnitude between 80 and 240 h after intravenous injection of a 0.25 mg/kg or 1.0 mg/
kg dose. During this time, concentrations in other tissues declined more slowly. In
another study, S-warfarin concentrations in serum and liver were followed for
approximately 50 days after intravenous injection of 1 mg/kg dose. This revealed a
very slow terminal elimination phase in serum nearly parallel to the decline in liver
warfarin concentrations. The residues of warfarin in liver of rats over time after a
single sublethal dose declined from 1.26 μg/g at 1 week, to below the limit of detection (<0.1 mg/g) at 24 weeks after dosing (combined results of 2 trials), with an
estimated liver-elimination half-life of 26.2 days (Fisher et al. 2003) (Table 4.2).
Although an effective anticoagulant, because of its low molecular weight, warfarin can readily cross the placenta; therefore, administration during pregnancy has
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Table 4.2 Half-life values reported for warfarin in blood and liver
Species
Norway rat
House mouse
Cat
Human
Human
Human (R isomer)
Human (S isomer)
Rats
Rats (ex-germ free)

Plasma t ½

Chicken

27.4 h (male)
34.0 h (female)

14.9 days*
26.2 h
42 h
35 h
20–60 h
18–35 h
6–41 h
18.2 h

Liver t ½
(days)
26.2
66.8

Reference
Fisher et al. (2003)
Vandenbroucke et al. (2008)
Smith et al. (2000b)
O’Reilly et al. (1963 )
Holford (1986)
Breckenridge et al. (1974); Hewick and
McEwen (1973); O’Reilly (1973, 1976;
O’Reilly et al. (1971); Orme and
Breckenridge (1976)
Yacobi et al. (1975)
Remmel et al. (1981)
Watanabe et al. (2015)

Plasma half-life significantly longer than that reported in other species (perhaps an artifact of high
dose levels).

consequences in regards to reduced mean birth weight (Sareli et al. 1989) and
increased percentage of abortion, stillbirth, and neonatal death incidences (Sareli
et al. 1989; Ginsberg and Hirsh 1989). The majority of the information regarding
coumarin anticoagulants in pregnancy has been derived from the use of warfarin to
prevent pulmonary embolism in pregnant women (Ginsberg and Hirsh 1989;
Greaves 1993). Howe and Webster (1992) showed that neonatal rats administered
subcutaneous warfarin and Vitamin K1 for up to 12 weeks developed marked maxillonasal hypoplasia. In humans, warfarin is a known teratogen that induces nasal
hypoplasia that can lead to neonatal respiratory distress and upper airway obstruction; stippled epiphyses marked by multiple ossification centers that severely deform
the long bone that could lead to dwarfism, and central nervous system defects such
as microcephaly, hydrocephalus, agenesis of corpus callosum, and Dandy-Walker
malformation have also been associated with warfarin exposure (Ginsberg and
Hirsh 1989). In addition, eye anomalies are also evidenced (optic atrophy, microphthalmia, and Peter anomaly of eye) (Hall 1990).
Pharmacokinetic studies of warfarin enantiomers indicate that significant differences exist in clearance of S- and R-warfarin in humans, rats and rabbits (Hignite
et al. 1980). These findings have also been confirmed in cats (Smith et al. 2000a),
with the enantiomers being highly protein-bound (>99%) at all concentrations evaluated, as described in other species (Brown et al. 1979). However, the binding affinity for both enantiomers to human and rat albumin appears to be significantly greater
than other species evaluated (Panjehshahin et al. 1992), and is enantioselective
appearing to have higher binding affinity for S-warfarin (Park 1988; Brown et al.
1979). Warfarin has also been detected in the albumen and yolk of hens eggs after
warfarin ingestion (Kammerer et al. 1998). The study suggests that the kinetics
involved are two fold – the first a direct diffusion of warfarin across the magnum
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wall of the chicken into the egg’s albumen one day after ingestion, and the second a
later accumulation at 3–4 days which appears to arise from liver depots. Although
appearing to be an effective elimination route, the amount of excretion into the egg
was minor compared to that excreted in urine and feces. However, as only the levels
of the parent warfarin were measured, the elimination efficiency and accumulated
levels of any metabolites remains unknown.

4.2

Coumatetralyl

The Danish Environmental Protection Agency (2011) produced a comprehensive
regulatory data dossier on coumatetralyl from which much of the following toxicokinetic information was summarized. As with other anticoagulants, in rats coumatetralyl is absorbed quickly after oral dosing. Maximum blood concentrations in rats
occurred at 3 h after single dosing in males and between 8 and 24 h in females, with
absorbed fraction estimates of 75% and 86% of total dose for males and females,
respectively. After single oral dosage of radiolabeled coumatetralyl, 49–56% of
administered radioactivity was retained in the body (excluding the gastrointestinal
tract). The largest fractions were found in liver (21–25%) and skin (7–16%). All
other organs retained less than 1% of the dose at sacrifice (Danish Environmental
Protection Agency 2011). Reported persistence and half-lives of coumatetralyl in
blood and liver are summarized in Table 4.3. Coumatetralyl has an intermediate
hepatic persistence in comparison to the SGARs.
The primary route of coumatetralyl excretion in rats is via urine and to a smaller
extent via feces, with respiratory (exhaled) excretion negligible. The rate of excretion was sex-dependent, where single-dosed males excreted about 20% of an administered dose in urine and about 20% in feces until sacrifice at 7 days. In comparison,
single-dosed females excreted about 37% in urine and about 12% in feces. With
repeated oral dosing, the ratio shifted towards 44% renal and 33% fecal excretion
until sacrifice, which was possibly due to enzyme induction over a 14 day period
(Danish Environmental Protection Agency 2011).

Table 4.3 Half-life values reported for coumatetralyl in blood and liver of rodents
Species
Norway rat
Norway rat
Norway rat
House mouse (Mus
musculus)
Red deer (Cervus
elaphus scoticus)

Plasma t ½
(hours)

71 (male)
46 (female)
12.5

Liver t ½
(days)
55
62

15.8

Reference
Parmar et al. (1987)
Eason et al. (2003)
Danish Environmental Protection
Agency (2011)
Vandenbroucke et al. (2008)

18.9

Crowell et al. (2013)
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Coumatetralyl is metabolized by hydroxylation, with four metabolites identified
in urine and feces. In rats, sex and dose did not have major effects on the metabolite
profiles. One main metabolite comprised 27% of the administered oral dose, with
three isomers of this main metabolite making up less than 10% of the dose. Two
further minor metabolites identified in urine (2% of the dose), with only traces of
unchanged coumatetralyl excreted in urine (Danish Environmental Protection
Agency 2011).

4.3

Chlorophacinone

As for other first- or intermediate-generation anticoagulants, chlorophacinone is
most efficacious when consumed in numerous doses over multiple days, i.e., a lethal
single dose requires a far greater quantity than the additive quantities that constitue
a lethal multiple/chronic dose (e.g., Jackson and Ashton 1992). In the rat, the main
route of chlorophacinone elimination is fecal (>99%). Belleville (1977) reported
that in a study of rats dosed with C14-labelled chlorophacinone, 90% was recovered
in the feces within 48 h of oral administration and 100% within 4 days. Biliary
excretion was investigated in this study, and it was found that 8 h after intraduodenal
chlorophacinone administration, 26% of the radioactivity was found in the bile,
providing further support that excretion in the feces is the main route of elimination.
Four hours after a single oral dose, concentration of chlorophacinone in the blood
reached its peak, and tissue to blood ratios were 4.2 for liver:blood, 0.9 for
kidney:blood and 0.6 for lung:blood (Belleville 1977). Berny et al. (2006) found the
oral bioavailability of chlorophacinone to be 92% in sheep with little degradation in
the rumen. Vein et al. (2013) found that rats from wild populations with known
resistance to ARs did not show any differences in profiles of hepatic accumulation
of chlorophacinone over 4 days following bait ingestion. In the same study, these
authors described extensive metabolism of chlorophacinone, with similar proportions
of three hydroxylated metabolite compounds produced by each strain of rat, with
one dominant metabolite accounting for approximately 50% of residual concentration in liver.
Two studies have examined chlorophacinone half-life in tissue (Table 4.4). Sheep
dosed intraruminally with 1 mg chlorophacinone/kg body weight had a time to
maximum plasma concentration of 30 h in contrast to intravenous dosing with
peaked values at the time of dosing (Berny et al. 2006). Half-lives of chlorophacinone in blood and liver are shown in Table 4.4.

Table 4.4 Half-life values for chlorophacinone in blood and liver
Species
Sheep
Mouse

Plasma t½ (hours)
30.1
11.7 days

Liver t½ (days)
35.4

Reference
Berny et al. (2006)
Vandenbroucke et al. (2008)
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Diphacinone

Like chlorophacinone, diphacinone is more toxic when ingested as consecutive,
multiple doses over a number of days (i.e., a lethal single dose requires a far greater
quantity than the additive quantities that constitue a lethal multiple/chronic dose).
For rodents, there are highly variable chronic oral toxicity estimates with apparent
differences in the susceptibility of male and female animals (e.g. Kusano 1974).
Reported persistence and half-lives of diphacinone in blood and liver are summarised in Table 4.5.
Yu et al. (1982) reported that diphacinone was not extensively metabolised by
rats following oral administration of C14-labelled diphacinone at 0.2 mg/kg or
1.5 mg/kg, with more than 60% of the dose excreted in feces and 10% in urine over
8 days, with the same elimination pattern observed in mice. Continued elimination
in feces over 4–8 days indicated that biliary excretion rather than incomplete absorption was the major route of elimination in both rodent species. At 8 days after dosing, rat tissues retained about 20% of radiocarbon (tracer in administered dose),
with highest concentration in the liver, substantial residues in kidney and lung, and
lower residues in brain, fat, blood and muscle (Yu et al. 1982). Another study, of
radio-labelled diphacinone administered orally to mice (Cahill and Crowder 1979)
reported similar results, with radioactivity reaching highest levels in liver and lungs,
with maximum liver concentrations at 3.0–7.5 h after administration. In an additional study of the excretion of radio-labelled diphacinone in mice, Cahill (1977)
did not detect unchanged diphacinone in feces, indicating the compound was likely
to be efficiently absorbed in the gastrointestinal tract and extensively metabolised,
prior to excretion of as-yet undefined metabolites in urine.
In contrast to findings in rodents, Bullard et al. (1976) reported that cows dosed
with 1 mg/kg diphacinone by intraruminal injection had almost constant liver
residues of up to 0.15 mg/g over 30–90 days after dosing. Another study by the
same group found mammillary transfer of diphacinone to milk of cows dosed
intraruminally with 2.75 mg/kg. The milk from these cows contained a maximum
concentration of 0.021 ppm diphacinone. They did not detect any diphacinone in the
Table 4.5 Half-life values reported for diphacinone in liver. Liver retention is expressed as the
time period for which residues are reported to persist in the liver unless the value is preceded by t½
Species
Norway rat
Cattle (Bos taurus)
Deer (Cervus elaphus scoticus)
Pig (Sus scrofa)
American kestrel (Falco sparverius)
Eastern screech-owl (Megascops asio)

Liver t½ (days)
t½ 3
>90
t½ 6 (mean)
t½ 5.43–14.12
t½ 12.4
t½ 0.325 (initial)
t½ 2.49 (terminal)
t½ 0.88 (initial)
t½ 29.2 (terminal)

Reference
Fisher et al. (2003)
Bullard et al. (1976)
Crowell et al. (2013)
Fisher (2006)
Crowell et al. (2013)
Rattner et al. (2011, 2014)
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milk of cows dosed with 1 mg/kg diphacinone, leading to the hypothesis that transfer of diphacinone to the milk is dependent on plasma concentration (Bullard et al.
1977). Recent research (Crowell et al. 2013) confirms that diphacinone is metabolised and distributed quite differently in cattle compared with in other mammals,
including exhibiting longer hepatic persistence.
In two studies investigating the effects of anticoagulants to non-target raptors,
Rattner and colleagues exposed both American kestrels (Falco sparverius) and
eastern screech owls (Megascops asio) to diphacinone. Kestrels were dosed with
diphacinone in a gelatin capsule at a range of 35.1–675 mg/kg body weight. In this
study, birds that succumbed within 24 h had greater liver residue levels than those
that died 27–47 h post dose, (32.8–56.3 μg/g liver and 13.4–19.4 μg/g liver, respectively). From these data, the clearance of diphacinone from the liver was determined to be biphasic with an initial half-life of 0.88 days (7.8 h) and a terminal
half-life of 29.2 days (Rattner et al. 2011). In a separate study, eastern screech owls
were provided diphacinone mixed into their diet for three or seven days for a
cumulative average dose of 4.74 mg/kg or 7.98 mg/kg body weight. During the
dosing period, kidney residue levels were greater than those found in the liver with
the concentration of diphacinone in both tissues decreasing rapidly in the postdose period being <0.1 μg/ g liver after three weeks. Clearance of diphacinone was
again found to be biphasic and cleared more rapidly from the kidney than the liver.
Initial half-life was found to be 0.88 days in liver and 0.14 days in kidney while
terminal half-life (day 4–21 post-dose) in liver of 29.2 days and kidney 10.2 days
(Rattner et al. 2014).

4.5

Pindone

Reported persistence and half-lives of pindone in blood and liver are summarised in
Table 4.6. In mammals, pindone is far less persistent than SGARs and also less
persistent in liver than other FGARs. In dogs, pindone was fairly well absorbed
(67%) but tissue distribution appeared to be slightly different from other anticoagulants, as plasma concentrations remained higher than tissue concentrations for
8 days, while concentrations in liver and kidney were comparable (Fitzek 1978).
Table 4.6 Half-life estimates for pindone in blood and liver
Species
Norway rat
Dog
Dog
Sheep
Sheep
Cattle
Chicken

Plasma t½ (hours)

Liver t½ (days)
2.1

120
45.6
8–16
96–120
74.4
67.2

Reference
Fisher et al. (2003)
Fitzek (1978)
Martin et al. (1991)
Nelson and Hickling (1994)
Robinson et al. (2005)
Martin et al. (1991)
Martin et al. (1991)
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In sheep, residues were detected in the liver and fat of dosed animals for 8 days,
but after 2 weeks no residues were detectable (Nelson and Hickling 1994). No
information was found about the excretion profile of pindone.

4.6

Brodifacoum

After ingestion and absorption of brodifacoum by mammals, high concentrations
are bound in the liver and remain stable, being slowly metabolised and excreted
(Erickson and Urban 2004). The persistence of brodifacoum in mammalian liver is
well documented and is in contrast with its more rapid elimination from blood
(Table 4.7). While no hepatic half-life values were found for avian species, limited
data suggests that birds have similarly prolonged persistence of brodifacoum in
liver. Brodifacoum concentrations in chicken livers showed little variation (mean
0.66, range 0.45–1.00 μg/g) over 14 days following sublethal oral exposure (Fisher
2009). Similarly, in Japanese quail (Coturnix japonica) orally administered brodifacoum (0.8 and 2.5 mg/kg body weight), there was no substantial decline in hepatic
concentrations over the following 5 days (Webster et al. 2015).
Table 4.7 Half-life values reported for brodifacoum in blood plasma/serum and liver following a
range of exposure levels and routes of administration. Liver retention is expressed as the time
period for which residues are reported to persist in the liver unless the value is preceded by t½.
Plasma is t½ unless otherwise specified
Species
Rat
Rat
Rat
Rat
Rat
Rat
Rat
Rat
Mouse
Rabbit
Dog
Dog
Dog
Possum
Sheep
Horse
Chicken

Plasma t½ (hours)

156 (serum)

2200.8
60.8 ± 1.9 (terminal)
144
21.6–112.8
1.4 (initial)
8.7 (terminal)
480–720

Liver retention
(days)
t½ 350
t½ 128 (terminal)
t½ 282
t½ 150–200
t½ 136
>80
t½ 130
t½ 113.5
t½ 307.4

>252
>250

28.8
27.36

Unpublished reports cited by Erickson and Urban (2004)

a

Reference
Batten and Bratt (1990)a
Batten & Bratt (1990)a
Hawkins et al. (1991)a
Bratt & Hudson (1979)a
Belleville (1991)a
Bachmann and Sullivan (1983)
Parmar et al. (1987)
Fisher et al. (2003)
Vandenbroucke et al. (2008)
Breckenridge et al. (1985)
Woody et al. (1992)
Robben et al. (1998)
Murphy et al. (1985)
Eason et al. (1996)
Laas et al. (1985)
Boermans et al. (1991)
Fisher (2009)
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Bachmann and Sullivan (1983) suggested that serum and liver concentrations of
brodifacoum were likely to accumulate with repeated daily exposures, based on simulations of the data they obtained following a single 0.2 mg/kg dose to laboratory rats.
The major route of excretion of unbound brodifacoum in mammals is through feces
(Sutcliffe et al. 1987). Field observations of rodent feces colored to different extents
by the green or blue dyes used in anticoagulant bait formulations are common - an
estimated 14–21.6% of ingested brodifacoum is excreted unchanged in rat feces in
the period between ingestion of a lethal amount of bait and death (Fisher 2009).
To better understand the pharmacokinetic properties of brodifacoum, Bachmann
and Sullivan (1983) gavaged male Sprague Dawley rats with varying doses of brodifacoum in polyethylene glycol 400. They found that metabolic processes play a
significant role in the efficacy of brodifacoum as pretreatment with SKF525A, a
non-selective cytochrome P450 inhibitor, increased the anticoagulant effect whereas
phenobarbital, cytochrome P450 inducer, decreased the anticoagulant effects
(Bachmann and Sullivan 1983).

4.7

Bromadiolone

Absorption of bromadiolone in laboratory rats was >70% of the administered dose,
based on carcass, bile and urinary excretion measurements (European Food Safety
Authority 2010). In rats given an oral dose of radiolabelled bromadiolone, within
48 h approximately 53% of was excreted in feces and <1% in urine (European Food
Safety Authority 2010). It seems that biliary elimination plays a major role, with
about 30% of an administered bromadiolone dose excreted in bile in the 8 h after
dosing (Nahas 1987). Bromadiolone is extensively metabolised to at least 10 minor
metabolites and 1 major metabolite, tentatively identified as a benzylic carbon
hydroxylated analogue of the parent compound. This metabolite is conjugated with
glucuronic acid before excretion in bile and hydrolysis in the gastrointestinal tract
(European Food Safety Authority 2010).
After oral administration to rats, bromadiolone was eliminated relatively quickly
from blood, resulting in high concentrations in liver tissues (Kamil 1987).
Elimination of radiolabelled bromadiolone from rat liver is reported to be biphasic,
consisting of a rapid initial phase lasting from 2 to 8 days after dosing and a slower
terminal phase (Anonymous 2010). Reported persistence and half-lives of bromadiolone in blood and liver are summarised in Table 4.8, noting an unusually long
half-life in blood of mice (Vandenbroucke et al. 2008). In a study using pigs, Enouri
et al. (2015) dosed two treatment groups with either 0.05 or 0.5 mg/kg bromadiolone and euthanized sub-groups at time points up to 9 weeks. Detectable levels of
bromadiolone were found in liver, skin and adherent fat, feces, and plasma three
week post-dosing. As expected, liver tissue had the highest bromadiolone residue
concentrations. Liver values for pigs dosed with 0.05 mg/kg were 51.8 μg/g at six
weeks while pigs dosed with 0.5 mg/kg bromadiolone had liver residues of
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Table 4.8 Half-life values reported for bromadiolone in blood and liver following a range of
exposure levels and routes of administration. Liver retention is expressed as the time period for
which residues are reported to persist in the liver unless the value is preceded by t½
Species
Norway rat (Rattus
norvegicus)
Norway rat
Rat
Sheep
Mouse

Blood t½
(hours)
26–57

Liver retention
(days)

25–26

t½ 170
318

33.3 days

256
28.1

Reference
Kamil (1987)
Parmar et al. (1987)
European Food Safety Authority
(2010)
Nelson and Hickling (1994)
Vandenbroucke et al. (2008)

213.9 μg/g at nine weeks post dosing. The authors also reported a biphasic depletion
of bromadiolone in the feces and that clearance was not dose-dependent in liver and
muscle tissues as the slope of the concentration vs time graphs were the same
regardless of dose administered (Enouri et al. 2015).

4.8

Difenacoum and Difethialone

There is limited information about the pharmacokinetics of difenacoum or difethialone. Vandenbroucke et al. (2008) cite an unpublished report (Bratt 1987) where an
oral dose of radiolabelled difenacoum (1.2 mg⁄ kg) administered to rats produced
the highest concentration of radioactivity in liver after 24 h, indicating a similar
timeframe of absorption as other anticoagulant compounds. Biphasic elimination of
difenacoum from liver and a terminal half-life of elimination of 118 days is also
cited (Vandenbroucke et al. 2008). In a 1985 study by Breckenridge and coworkers,
male New Zealand rabbits were intravenously dosed with difenacoum dissolved in
polyethylene glycol 200. Difenacoum exhibited a biphasic decay in the plasma with
a terminal half-life of 83.1 h. This terminal half-life is much great than that for warfarin, which was attributed to difenacoum’s greater volume of distribution relative
to warfarin (Breckenridge et al. 1985). In their assessment of multiple anticoagulant
compounds in mice, Vandenbroucke et al. (2008) estimated plasma elimination
half-lives of 20.4 and 38.9 days for difenacoum and difethialone, respectively, and
liver elimination half-lives of 61.8 and 28.5 days, respectively. In a study of dogs
administered a range of anticoagulant compounds, Robben et al. (1998) estimated
plasma half-life of difethialone in two animals of 2.2 and 3.2 days. More recently,
Damin-Pernik et al. (2016a) showed that while cis- and trans-isomers of difenacoum were similarly absorbed after oral administration to laboratory rats, in liver
the half-life of the trans-isomers were 24.2 h compared to 706 h for the
cis-isomers.
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Table 4.9 Half-life values reported for flocoumafen in liver following a range of exposure levels
and routes of administration. Liver retention is expressed as the period for which residues are
reported to persist in the liver unless the value is preceded by t½
Species
Norway rat (Rattus norvegicus)
Sheep
Quail (Coturnix coturnix)
Dog
Mouse (Mus musculus)

4.9

Liver retention (days)
t1/2 220
>256
t1/2 > 100
>300
93.8

Reference
Huckle et al. (1988)
Nelson and Hickling (1994)
Huckle et al. (1989b)
Veenstra et al. (1991)
Vandenbroucke et al. (2008)

Flocoumafen

In rats, absorption of orally-administered flocoumafen is rapid, reaching a maximum concentration in blood after 4 h and falling to half-maximum by 8 h (Huckle
et al. 1989a). The persistence of flocoumafen in liver is of a similar extent to that of
brodifacoum (Table 4.9). A plasma half-life of flocoumafen in mice was estimated
as 26.6 d (Vandenbroucke et al. 2008), consistent with the overall shorter retention
time of anticoagulants in blood compared to liver.
Following administration of flocoumafen, liver residues in rats consisted mainly
of unchanged flocoumafen, although in a repeat-dose study a polar metabolite was
also detected. Eight urinary metabolites were detected after percutaneous exposure
to 14C–flocoumafen but represented a small proportion of the total dose, with most
excretion occurring in the feces as unchanged flocoumafen (Huckle and Warburton
1986 cited by Eason and Wickstrom (2001)). Veenstra et al. (1991) found retention
of about 8% of an administered flocoumafen dose of 0.4 mg/kg in the liver of beagle
dogs 300 days after dosing. When oral 14C–flocoumafen doses of 0.02 mg/kg or
0.1 mg/kg body weight were given to rats, once weekly for up to 14 weeks, approximately one-third of each weekly low dose was eliminated through the feces within
3 days, mostly within the first 24 h. At the higher dose, the fecal excretion ranged
from 18% after the first dose to 59% after the 10th dose (Huckle et al. 1988). This
study indicated the potential of flocoumafen to bioaccumulate in rat liver, as hepatic
residues increased throughout the 14 week repeat-dosing period.
Japanese quail metabolize flocoumafen more rapidly than rats, with a proportion
of an administered dose retained in the liver and an elimination half-life of 155 days.
In quail, fecal excretion of radio-labelled flocoumafen following an oral dose of
0.14 mg/kg body weight accounted for 23–26% of the dose over the 7-day period;
approximately half of this was recovered within the first 24 h with less than 0.5% of
the dose excreted in urine within 7 days (Huckle et al. 1989b).
In a dietary toxicity study, 30-week-old laying hens were fed a diet designed to
produce different exposures to flocoumafen (1.5, 5, 10 and 50 mg/kg) over five
consecutive days (Eadsforth et al. 1993). The LC50 at the end of a 28-day observation period was 16.4 mg/kg. Livers of birds administered 5–50 mg/kg had concentrations of flocoumafen (1.5 nmol/g) that were independent of dose, indicating a
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saturable high-affinity binding site in liver. While residual flocoumafen in the
corresponding muscle samples was at relatively low concentrations in all treatment
groups, higher dose-related residues were found in samples of abdominal and
skin-associated fat and there was clear evidence of the transfer of dose-related residues into eggs. Eadsforth and colleagues also describe another study in which hens
were dosed with [14C]flocoumafen for five consecutive days at a daily rate of 1 mg/
kg or 4 mg/kg body weight, where 68% of the daily radioactive dose was eliminated
over the following 24 h via excreta (Eadsforth et al. 1993). Residues in liver at death
through poisoning or at euthanasia accounted for <1% of the cumulative administered radioactivity. Residues in eggs at 10 days after first exposure were primarily in
the yolk with maximum concentrations of 1.0 mg/kg (0.18% of the low dose) and
2.1 mg/kg (0.06% of the high dose), with 40% of the total activity in the yolk
comprising unchanged flocoumafen (measured as 14C- flocoumafen equivalents).

5

Toxicokinetics of Anticoagulant Rodenticides

While the mechanism of action of warfarin (i.e., coumadin) and its time course of
therapeutic effect (i.e., prolonged prothrombin time) have been thoroughly investigated in man (e.g., Holford 1986; Sutcliffe et al. 1987), remarkably few studies have
examined the time course of AR toxicity (i.e., coagulopathy) and clotting time
recovery that accompanies exposure in non-target animals. Following administration of a therapeutic dose or a toxic dose(s) and the inhibition of vitamin K epoxide
reductase, there is a lag period of several days prior to the appearance of prolonged
clotting time. This lag period (2–3 days) reflects the clearance half-life of fully-
functional coagulation factors, for example, half-life of factors II, VII, IX and X in
man are 120 h, 6 h, 18 h and 65 h, respectively(Lee et al. 2006) accompanied by the
appearance of increasing quantities of des-carboxy dysfunctional factors that are
unable to assemble on cell surfaces to form active coagulation complexes. A detailed
study in which domestic cats received a single intravenous bolus dose of racemic
warfarin (0.5 mg/kg) describes maximum prothrombinopenic effects within
24–48 h, and recovery of prothrombin complex activity to pre-exposure baseline
levels within 70 h (Smith et al. 2000b). However, in this study inter-individual variation among cats was substantial, as has been noted in man. A study in domestic dogs
administered warfarin (5 mg/kg) or diphacinone (2.5 mg/kg) as divided doses for
3 days demonstrated prolonged clotting time within 2–3 days (Mount and Feldman
1983). While administration of a single dose of vitamin K1 (5 mg/kg) restored
clotting function in the warfarin-treated dog within 24–48 h, multiple vitamin K1
doses were required in diphacinone-dosed dogs as they exhibited impaired clotting
function for as long as 30 days.
Few studies have examined toxicokinetics of ARs in non-target wildlife. Dietary
exposure of golden eagles (Aquila chrysaetos) to 2.7 μg diphacinone/g ww resulted
in prolonged clotting time within 5 days with coagulopathy apparent at least 5 days
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post-exposure (Savarie et al. 1979). Similarly, Eastern screech-owls (Megascops
asio) fed a diet containing 10 μg diphacinone/g ww exhibited coagulopathy within
3 days, and upon termination of exposure clotting function was restored within
4 days (Rattner et al. 2014). As alluded to in Chap. 3 of the text, latent episodes
of hemorrhage, occurring days to weeks following termination of AR exposure,
have been observed in some trials in non-target wildlife.

6

Conclusions

Although ARs have been in use for decades, there are relatively little data on the
ADME properties and binding properties of these compounds. These data are
challenging to obtain but are invaluable for many reasons. ADME data is important
for the basic understanding of anticoagulant compounds enabling scientists to
compare anticoagulants to other classes of contaminants and therapeutics. These data
are also used to evaluate the comparative efficacy of anticoagulants and to develop
hazard and risk assessments. These risk assessments are used by the US EPA and
comparative international agencies to evaluate registration and use of these products.
ADME data is often used in risk assessment models; therefore, the better the pool
of data from which to draw, the more robust the risk assessment.
Numerous areas of research of anticoagulants may need further study to determine what, if any, effect role they play in non-target risk. These include placental
and in ovo transfer of residues. Both of these may represent significant routes
of exposure to anticoagulant compounds, and surprisingly have not been well-
characterized. Also, fecal excretion of anticoagulants has not been well studied.
Fecal excretion may contribute significantly to the transfer of anticoagulant compounds across the environment. From the few available reports, excretion of parent
compound or metabolite is compound dependent with some anticoagulants being
excreted in the feces as metabolites while others are excreted in high percentages
as parent compound.
Additional studies investigating basic ADME properties of anticoagulants need
to be conducted. These include competitive binding studies to determine the active
binding sites of these compounds. This information would both improve risk assessments when exposure to multiple compounds is being considered and to assess the
potential for cumulative toxicities. Recently published studies have examined the
pharmacokinetic properties of various SGAR diastereoisomers and their ability to
inhibit vitamin K epoxide reductase (VKOR) (Damin-Pernik et al. 2016a, b). It was
demonstrated that cis- and trans- SGAR isomers exhibit similar potency in their
ability to inhibit VKOR, but their pharmacokinetic properties differ considerably.
This research team has suggested that it might be possible to create eco-friendly
baits that are efficacious in controlling pest species, but with the shorter tissue
half-life SGAR isomer that would pose less risk to non-target predators consuming
poisoned prey.
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